litlas
Log inCreate account

Joan H. Schiller

Active 1991–2025

97
Papers
37,501
Citations
83
h-index
96
i10-index

Citations

Citations per year for Joan H. Schiller1993: 3 citations1994: 2 citations1995: 5 citations1996: 6 citations1997: 8 citations1998: 7 citations1999: 8 citations2000: 10 citations2001: 19 citations2002: 48 citations2003: 79 citations2004: 173 citations2005: 326 citations2006: 301 citations2007: 317 citations2008: 304 citations2009: 430 citations2010: 437 citations2011: 406 citations2012: 382 citations2013: 377 citations2014: 271 citations2015: 302 citations2016: 321 citations2017: 264 citations2018: 272 citations2019: 856 citations2020: 809 citations2021: 737 citations2022: 522 citations2023: 345 citations2024: 532 citations2025: 197 citations2026: 6 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,180 citing papers, 27.3% of this breakdownChina: 1,367 citing papers, 11.8% of this breakdownJapan: 637 citing papers, 5.5% of this breakdownUnited Kingdom: 577 citing papers, 5% of this breakdownItaly: 550 citing papers, 4.7% of this breakdownGermany: 467 citing papers, 4% of this breakdownCanada: 454 citing papers, 3.9% of this breakdownFrance: 424 citing papers, 3.6% of this breakdownSpain: 382 citing papers, 3.3% of this breakdownSouth Korea: 302 citing papers, 2.6% of this breakdownNetherlands: 293 citing papers, 2.5% of this breakdownAustralia: 271 citing papers, 2.3% of this breakdown
0%27.3%Other 23.5%

Institutions

Fields

  • Medicine70.2%
  • Biochemistry, Genetics and Molecular Biology21.2%
  • Immunology and Microbiology2.6%
  • Computer Science0.7%
  • Chemistry0.7%
  • Materials Science0.7%
  • Other3.9%

Topics

  • Lung Cancer Treatments and Mutations14.7%
  • Lung Cancer Research Studies7.1%
  • Lung Cancer Diagnosis and Treatment6.4%
  • Cancer Immunotherapy and Biomarkers4.2%
  • Cancer Genomics and Diagnostics3.2%
  • HER2/EGFR in Cancer Research2.3%
  • Other62.1%

Coauthors

All papers

Open in search
  1. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

    Authors: Mark G. Kris, Bruce E. Johnson, Lynne D. Berry, David J. Kwiatkowski, A. John Iafrate, Ignacio I. Wistuba, Marileila Varella‐Garcia, Wilbur A. Franklin, Samuel L. Aronson, Pei-Fang Su, Yu Shyr, D. Ross Camidge, Lecia V. Sequist, Bonnie S. Glisson, Fadlo R. Khuri, Edward B. Garon, William Pao, Charles M. Rudin, Joan H. Schiller, Eric B. Haura, Mark A. Socinski, Keisuke Shirai, Heidi Chen, Giuseppe Giaccone, Marc Ladanyi, Kelly Kugler, John D. Minna, Paul A. Bunn - JAMA 2014 cited by 1,744

  2. Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

    Authors: Alan Sandler, Robert J. Gray, Michael C. Perry, Julie R. Brahmer, Joan H. Schiller, Afshin Dowlati, Rogério Lilenbaum, David H. Johnson - New England Journal of Medicine 2006 cited by 5,778

  3. Lung cancer in never smokers — a different disease

    Authors: Sophie Sun, Joan H. Schiller, Adi F. Gazdar - Nature reviews. Cancer 2007 cited by 1,602

  4. Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

    Authors: Nasser H. Hanna, Bryan J. Schneider, Sarah Temin, Sherman Baker, Julie R. Brahmer, Peter M. Ellis, Laurie E. Gaspar, Rami Y. Haddad, Paul J. Hesketh, Dharamvir Jain, Ishmael Jaiyesimi, David H. Johnson, Natasha B. Leighl, Tanyanika Phillips, Gregory J. Riely, Andrew Robinson, Rafael Rosell, Joan H. Schiller, Navneet Singh, David R. Spigel, Janis O. Stabler, Joan Tashbar, Gregory A. Masters - Journal of Clinical Oncology 2020 cited by 455

  5. Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

    Authors: Joan H. Schiller, David Harrington, Chandra P. Belani, Corey J. Langer, Alan Sandler, James E. Krook, Junming Zhu, David H. Johnson - New England Journal of Medicine 2002 cited by 4,984

  6. Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

    Authors: Nasser H. Hanna, Andrew Robinson, Sarah Temin, Sherman Baker, Julie R. Brahmer, Peter M. Ellis, Laurie E. Gaspar, Rami Y. Haddad, Paul J. Hesketh, Dharamvir Jain, Ishmael Jaiyesimi, David H. Johnson, Natasha B. Leighl, Pamela R. Moffitt, Tanyanika Phillips, Gregory J. Riely, Rafael Rosell, Joan H. Schiller, Bryan J. Schneider, Navneet Singh, David R. Spigel, Joan Tashbar, Gregory A. Masters - Journal of Clinical Oncology 2021 cited by 301

  7. Air Pollution and Lung Cancer: A Review by International Association for the Study of Lung Cancer Early Detection and Screening Committee

    Authors: Christine D. Berg, Joan H. Schiller, Paolo Boffetta, Jing Cai, Casey Connolly, Anna Kerpel-Fronius, Andrea Borondy Kitts, David Lam, Anant Mohan, Renelle Myers, Tejas Menon Suri, Martin C. Tammemägi, Dawei Yang, Stephen Lam - Journal of Thoracic Oncology 2023 cited by 162

  8. Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline

    Authors: Navneet Singh, Sarah Temin, Sherman Baker, Elizabeth Blanchard, Julie R. Brahmer, Paul Celano, Narjust Duma, Peter M. Ellis, Ivy B. Elkins, Rami Y. Haddad, Paul J. Hesketh, Dharamvir Jain, David H. Johnson, Natasha B. Leighl, Hirva Mamdani, Gregory A. Masters, Pamela R. Moffitt, Tanyanika Phillips, Gregory J. Riely, Andrew Robinson, Rafael Rosell, Joan H. Schiller, Bryan J. Schneider, David R. Spigel, Ishmael Jaiyesimi - Journal of Clinical Oncology 2022 cited by 124

  9. Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline

    Authors: Navneet Singh, Sarah Temin, Sherman Baker, Elizabeth Blanchard, Julie R. Brahmer, Paul Celano, Narjust Duma, Peter M. Ellis, Ivy B. Elkins, Rami Y. Haddad, Paul J. Hesketh, Dharamvir Jain, David H. Johnson, Natasha B. Leighl, Hirva Mamdani, Gregory A. Masters, Pamela R. Moffitt, Tanyanika Phillips, Gregory J. Riely, Andrew Robinson, Rafael Rosell, Joan H. Schiller, Bryan J. Schneider, David R. Spigel, Ishmael Jaiyesimi - Journal of Clinical Oncology 2022 cited by 113

  10. Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

    Authors: Joachim von Pawel, Joan H. Schiller, Frances A. Shepherd, Scott Z. Fields, J P Kleisbauer, Nick G. Chrysson, David J. Stewart, Peter Clark, Martin Palmer, A Depierre, James Carmichael, Jacqueline B. Krebs, Graham Ross, Stephen Lane, Richard J. Gralla - Journal of Clinical Oncology 1999 cited by 960

  11. A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Non–Small Cell Lung Cancer Patients

    Authors: Hao Tang, Guanghua Xiao, Carmen Behrens, Joan H. Schiller, Jeffrey A. Allen, Chi‐Wan Chow, Milind Suraokar, Alejandro H. Corvalán, Jian‐Hua Mao, Michael A. White, Ignacio I. Wistuba, John D. Minna, Yang Xie - Clinical Cancer Research 2013 cited by 291

  12. A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer

    Authors: Alberto Chiappori, Tatjana Kolevska, David R. Spigel, Steven Hager, Mark U. Rarick, Shirish M. Gadgeel, Normand Blais, Joachim von Pawel, L. Hart, Martin Reck, Ekaterina Bassett, Bart Burington, Joan H. Schiller - Annals of Oncology 2014 cited by 178

  13. Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

    Authors: Nasser H. Hanna, David H. Johnson, Sarah Temin, Sherman Baker, Julie R. Brahmer, Peter M. Ellis, Giuseppe Giaccone, Paul J. Hesketh, Ishmael Jaiyesimi, Natasha B. Leighl, Gregory J. Riely, Joan H. Schiller, Bryan J. Schneider, Thomas J. Smith, Joan Tashbar, William A. Biermann, Gregory A. Masters - Journal of Clinical Oncology 2017 cited by 650

  14. Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

    Authors: Gregory A. Masters, Sarah Temin, Christopher G. Azzoli, Giuseppe Giaccone, Sherman Baker, Julie R. Brahmer, Peter M. Ellis, Ajeet Gajra, Nancy Rackear, Joan H. Schiller, Thomas J. Smith, John R. Strawn, David Trent, David H. Johnson - Journal of Clinical Oncology 2015 cited by 851

  15. Phase Ia Study of Anti-NaPi2b Antibody–Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non–Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer

    Authors: David E. Gerber, Jeffrey R. Infante, Michael S. Gordon, Sarah B. Goldberg, Miguel Martín, Enriqueta Felip, Maria Martinez‐García, Joan H. Schiller, David R. Spigel, Julie Cordova, Valerie Westcott, Yulei Wang, David S. Shames, YounJeong Choi, Robert S. Kahn, Randall Dere, Divya Samineni, Jian Xu, Kedan Lin, Katie Wood, Stephanie Royer‐Joo, Vanessa Lemahieu, Eva Schuth, Anjali Vaze, Daniel Maslyar, Eric W. Humke, Howard A. Burris - Clinical Cancer Research 2019 cited by 53

  16. Hereditary Lung Cancer Syndrome Targets Never Smokers with Germline EGFR Gene T790M Mutations

    Authors: Adi Gazdar, Linda Robinson, Dwight Oliver, Chao Xing, William D. Travis, Junichi Soh, Shinichi Toyooka, Lori Watumull, Yang Xie, Kemp H. Kernstine, Joan H. Schiller - Journal of Thoracic Oncology 2014 cited by 153

  17. Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer

    Authors: Mark G. Kris, Ronald B. Natale, Roy S. Herbst, T. J. Lynch, Diane Prager, Chandra P. Belani, Joan H. Schiller, Karen Kelly, H. Spiridonidis, Alan Sandler, Kathy S. Albain, David Cella, Michael Wolf, Steven D. Averbuch, Judith Ochs, Andrea Kay - JAMA 2003 cited by 2,538

  18. Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

    Authors: Giuseppe Giaccone, Roy S. Herbst, Christian Manegold, Giorgio V. Scagliotti, Rafael Rosell, Vincent A. Miller, Ronald B. Natale, Joan H. Schiller, Joachim von Pawel, A Płużańska, U. Gatzemeier, John Grous, Judith Ochs, Steven D. Averbuch, Michael Wolf, Pamela Rennie, Abderrahim Fandi, David H. Johnson - Journal of Clinical Oncology 2004 cited by 1,720

  19. Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis

    Authors: Andrea Ardizzoni, Luca Boni, Marcello Tiseo, Frank V. Fossella, Joan H. Schiller, Marianne Paesmans, Davorin Radosavljević, Adriano Paccagnella, Petr Zatloukal, Paola Mazzanti, D. Bisset, R. Rosell - JNCI Journal of the National Cancer Institute 2007 cited by 608

  20. Stigma among patients with lung cancer: a patient-reported measurement model

    Authors: Heidi Hamann, Jamie S. Ostroff, Emily Marks, David E. Gerber, Joan H. Schiller, Simon J. Craddock Lee - Psycho-Oncology 2013 cited by 169

  21. Body Mass Index and Its Association with Clinical Outcomes for Advanced Non–Small-Cell Lung Cancer Patients Enrolled on Eastern Cooperative Oncology Group Clinical Trials

    Authors: Suzanne E. Dahlberg, Joan H. Schiller, Philip Bonomi, Alan B. Sandler, Julie R. Brahmer, Suresh S. Ramalingam, David H. Johnson - Journal of Thoracic Oncology 2013 cited by 110

  22. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

    Authors: Dara L. Aisner, Lynette M. Sholl, Lynne D. Berry, Michael R. Rossi, Heidi Chen, Junya Fujimoto, André L. Moreira, Suresh S. Ramalingam, Liza C. Villaruz, Gregory A. Otterson, Eric B. Haura, Katerina Politi, Bonnie S. Glisson, Jeremy Cetnar, Edward B. Garon, Joan H. Schiller, Saiama N. Waqar, Lecia V. Sequist, Julie R. Brahmer, Yu Shyr, Kelly Kugler, Ignacio I. Wistuba, Bruce E. Johnson, John D. Minna, Mark G. Kris, Paul A. Bunn, David J. Kwiatkowski - Clinical Cancer Research 2017 cited by 218

  23. Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies

    Authors: Hao Tang, Sophia Mei Wang, G. Xiao, Joan H. Schiller, Vassiliki A. Papadimitrakopoulou, J D Minna, Ignacio I. Wistuba, Yang Xie - Annals of Oncology 2017 cited by 108

  24. Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non–Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508)

    Authors: Jyoti D. Patel, Ju-Whei Lee, David P. Carbone, Henry Wagner, Anil Shanker, Maria Teresa P. de Aquino, Leora Horn, Melissa L. Johnson, David E. Gerber, Jane Jijun Liu, Millie Das, Mohammed Ali Al-Nsour, Christopher Dakhil, Suresh S. Ramalingam, Joan H. Schiller - Clinical Lung Cancer 2020 cited by 23